Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinwei Jiaonang
- Development stage
- Phase 2
- Lead developer
- Sichuan Academy of Chinese Medical Sciences
- Administration
- Oral
01
Overview
Qinwei Jiaonang is a traditional Chinese medicine (TCM) capsule developed by the Sichuan Academy of Chinese Medicine Sciences for the treatment of nonalcoholic steatohepatitis (NASH). It is specifically formulated for patients presenting with the TCM pattern of damp-heat accumulation. The drug is currently being evaluated in a randomized, double-blind, placebo-controlled Phase II clinical trial in China (CTR20240691) to determine its efficacy, safety, and optimal dosage in adults with biopsy-confirmed NASH. As a botanical formulation, it likely exerts its therapeutic effects through multi-target modulation of metabolic and inflammatory pathways associated with hepatic steatosis and fibrosis.
- Brand names
- Qinwei Jiaonang
Beyond the preview
Go deeper on Qinwei Jiaonang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qinwei Jiaonang.